The prognosis of metastatic malignant mesenchymal tumors (MMT) remains poor. Given the chemosensitivity of these neoplasms, a phase II study of high-dose thiotepa (HDT) was performed to evaluate the efficacy of this drug in this particular subset of pediatric tumors. Between 1986 and 1998, 18 patients, previously treated with conventional therapy for metastatic or refractory MMT, entered the study. Thiotepa was administered at a daily dose of 300 mg/m 2 for 3 consecutive days. Hematopoietic stem cell rescue, consisting of bone marrow transplantation or peripheral stem cell transplantation, was performed 2 days after completion of HDT. A response exceeding 50% was observed in 6/18 patients (response rate 33%). Toxicity was severe but never led to death. HDT used at a dose of 900 mg/m 2 yields measurable anti-tumor activity in previously treated patients. The next step in these particularly poor prognosis metastatic MMT will be to investigate HDT combined with other drugs, known to be efficient at high doses. Bone Marrow Transplantation (2000) 26, 627-632. Keywords: thiotepa; BMT; rhabdomyosarcoma; sarcoma; children Metastatic malignant mesenchymal tumors are rare but have a notoriously poor outcome. In stage IV rhabdomyosarcoma (RMS), for example, conventional chemotherapy combined with local treatment yields a cure rate of approximately 20%. As RMS is a chemosensitive tumor, it was thought that high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation could potentially improve the outcome of patients afflicted by these tumors. The dose-effect relationship is essentially effective in chemosensitive malignancies. High-dose thiotepa has yielded significant anti-tumor activity in a variety of pediatric solid tumors.
Patients and methods

Patient characteristics
From 1986 to 1998, 18 children treated for a malignant mesenchymal tumor, entered a phase II study of high-dose thiotepa (HDT) followed by hematopoietic stem cell transplantation (HSCT), in four different SFOP centers. All patients had recurrent disease or lesions that were refractory to first-line conventional chemotherapy. The sex ratio was 11 boys/7 girls. The median age at diagnosis was 10.5 years (range 2-18.5).
The histologic types were six alveolar rhabdomyosarcoma (RMS), eight embryonal RMS, two desmoplastic sarcoma, and two undifferentiated sarcoma.
At the time of diagnosis, disease was classified as stage IV in nine patients, stage III in four, stage II in two and stage I in three (Table 1) according to the TNM classification. 3 Before entering this HDT phase II study, all patients had received conventional chemotherapy with three to 10 different drugs (median six), according to SIOP protocols MMT 75, MMT 84, MMT 89, MMT95. [4] [5] [6] [7] The primary tumor (PT) had been resected in seven patients. Three of the seven excisions had been considered microscopically complete. In one patient (No. 16) pulmonary metastases had been resected. Surgery had not been performed when tumors were unresectable after chemotherapy or when there was no macroscopic tumor, depending on the protocol applied. In eight patients, local treatment had also comprised radiotherapy to the primary tumor bed at a median dose of 45.Gy (range 39-50).
After first-line chemotherapy, six patients (Nos 2, 3, 8, 10, 11, 17) had shown no signs of response and were considered to have primary disease refractory (RD) to chemotherapy (radiologically evaluated response Ͻ25%). A partial remission (PR) had been obtained in two patients with metastatic lesions (Nos 6, 7). The 10 remaining patients had developed recurrent lesions (from one to six), after having achieved complete remission (CR) (details for each patient are given in Table 2 ).
Treatment of recurrent disease had consisted of secondline chemotherapy for all 10 relapsing patients, surgical excision of a local recurrence in one patient (No. 9), radiotherapy to the PT in two others (Nos 15, 18) (45 Gy) and both surgical excision and radiotherapy to the PT in six patients (Nos 1, 4, 5, 13, 14, 16) (45 Gy). One patient had Response: PD = progressive disease; PR = partial remission; RD = refractory disease; RR = refractory relapse; S = sensitive. Localization: B = bone; CNS = central nervous system; L = lung; Li = liver; LN = lymph node; Met = metastases; PT = primary tumor; Sp = spleen. Chemotherapy: Adria = adriamycin; Cb = carboplatin; Cp = cisplatinum; Cpm = cyclophosphamide ; CEV = carboplatin, epirubicin, vincristine; Epi = epirubicin; Genc = gencytabine; IVA = ifosfamide, vincristine, actinomycin D; IVE = ifosfamide, vincristine, etoposide; MOPP = nitrogen mustard, vincristine, procarbazine, prednisone; Pcb = procarbazine; VAC = vincristine, actinomycin D, cyclophosphamide; VINCAEPI = vincristine, carboplatin, teniposide; VP16 = etoposide; Thep = theprubicin.
also received interleukin 2 (350 000 IU/kg × 4 days) (No. 4). Of the 10 relapsing patients, two (Nos 4, 9) had a refractory recurrence and in two, the sensitivity of the relapse had not been tested and HDT was the first treatment proposed (Nos 12, 15). The other six patients had sensitive relapses.
Finally, at the time of HDT, four patients were in partial remission and 14 had progressive disease (progression over 25% at any sites of the disease).
All patients had measurable disease, at the primary site (five patients), at metastatic sites (six patients) and at both sites (seven patients). Metastases were located in the lungs 
Response: DOD = died of disease; OE = objective effect; NED = no evidence of disease; PD = progressive disease; PR = partial remission; SD = stable disease. Location: PT = primary tumor; met = metastases.
(seven patients), bone (one patient), lymph nodes (six patients), central nervous system (one patient), and the pleura (one patient).
Drug administration and transplantation procedures
Thiotepa was administered at a daily dose of 300 mg/m 2 /day as a 1-h infusion, for 3 consecutive days (total dose of 900 mg/m 2 ). HSCT was performed 2 or 3 days after the end of chemotherapy. Seven patients had an autologous bone marrow transplantation (ABMT), eight had a peripheral blood stem cell (PBSC) graft and three patients received both ABMT and PBSC. PBSC were obtained by leukaphereses and mobilized using G-CSF administered to patients in steady state or at recovery following myelosuppressive chemotherapy.
Supportive care
All patients were isolated in a laminar air-flow room and were fitted with a right atrial catheter on admission to the transplantation unit. Broad-spectrum antibiotics were prescribed, as previously described. 8 Platelet and packed red blood cell transfusions were prescribed to maintain the platelet count Ͼ20 × 10 9 /l and hemoglobin Ͼ70 g/l. All blood products were irradiated at a dose of 25 Gy before transfusion and CMV-negative products were given to CMVseronegative patients.
Evaluation of response
Tumor response was evaluated 4-6 weeks after transplantation. The aim of the evaluation, using CT scan or MRI, and/or scintigraphy and/or medullogram, was to measure
Bone Marrow Transplantation changes in the tumor volume at all disease sites, primary tumor and measurable metastases included. Complete remission (CR) was defined as no detectable disease, whatever the investigation. A partial response corresponded to shrinkage of previous volumes exceeding 50%. No response (NR) denoted an objective effect (OE) which was defined as a reduction of between 25% and 50%, stable disease (SD) corresponding to tumor shrinkage of less than 25% and progressive disease (PD).
Results
Tumor response
All patients were evaluable for tumor response (Table 3) and toxicity.
Of the 18 patients, one achieved CR (No. 18), five achieved PR (Nos 1, 2, 13, 15, 17) , and all the others were considered as NR ( Table 3) . Six of 18 patients responded following HDT attaining a response rate of 33% (95% CI 11% to 55%).
Twelve of the 18 patients received further treatment after HDT. The patient who entered CR (No. 18) after HDT relapsed locally 7 months later and is now alive with PD.
Among the five patients who achieved PR, one (No. 17) received a second course of HDT with HSCT. In spite of this treatment, he died of progressive disease 2 months later. Another patient (No. 13) had resection of lung metastases followed by thoracic radiotherapy and is still considered to have stable disease 16 months later. The three others (Nos 1, 2, 15) died of progressive disease despite further surgery in two cases and radiotherapy in one.
Among the 12 non-responders, 10 died of progressive disease after HDT despite various post-transplantation treatments over a median of 4 months (range 2-31). Two patients (Nos 7, 8) are still alive with NED, 63+ and 50+ months post HDT. One received radiotherapy to the primary tumor and the other had additional chemotherapy including cyclophosphamide and carboplatin and surgical resection of lung metastases. Thus, four patients are currently alive, two of them with NED and a duration of follow-up of 16+, 22+, 50+ and 63+ post HDT. The overall median time to relapse post HDT was 4 months (range 1-21) with a median follow-up of 8 months (range 2-63).
Toxicity
No patient died of HDT-related toxicity. Although the toxicity of thiotepa was significant, overall tolerance was acceptable in this study. Myelosuppression was the most common toxicity observed. The median duration of neutropenia (Ͻ0.5 × 10 9 /l) and thrombocytopenia (Ͻ50 × 10 9 /l) was 9.5 days (range 2-37) and 30 days (6-140), respectively. According to the current protocol at time of BMT, 12 of 18 patients received G-CSF systematically after the transplantation procedure: all PBSC recipients, two ABMT recipients and two patients who received both grafts. The median duration of G-CSF administration was 13 days (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .
The median number of red blood cell and platelet transfusions was two (range 1-4) and four (range 2-13), respectively.
All patients experienced fever during neutropenia for a median duration of 6 days (range 1-18). In the majority of cases, its origin remained unknown. A bacterial isolate was identified in three cases. Two patients had septicemia due to Enterobacter cloacae in one case and to Staphylococcus aureus in the other. One patient had a urine infection due to Enterococcus. These infections resolved easily with no complications. The median duration of antibiotic therapy was 17 days (range .
No severe hemorrhagic complications occurred during hospitalisation post SCT. One case of mild hemorrhagic cystitis was reported that resolved completely.
Two patients experienced acute renal toxicity (tubular pathology and a decrease in creatinine clearance). These complications were transient and recovery was complete and rapid.
Mucositis was observed in 12/18 patients. In seven cases, this side-effect exceeded grade 2 according to the Bearman classification. 9 Fourteen of 18 patients experienced vomiting despite regular prophylactic ondansetron.
Diarrhoea occurred in 13/18 patients and was severe in eight (three grade III and five grade II). Treatment led to anorexia in 15/18 children which was severe in four. Weight loss was severe (Ͼ10% of body weight) in three cases.
Four cases of skin toxicity were documented, one of which was described as lobster syndrome. The patient recovered from this toxicity slowly and there were no late effects.
Discussion
Although the prognosis of localized RMS has improved over the last 20 years, with overall survival reaching 60% to 70%, 10 the prognosis of metastatic or recurrent RMS remains very poor (15-30% according to studies). [11] [12] [13] The cure rate of high-risk rhabdomyosarcoma, namely primary or secondary metastatic disease, parameningeal and localized tumors refractory to conventional therapy, is evaluated at around 20%.
14 Since RMS is a chemosensitive tumor, dose escalation is considered a valid option in attempts to improve the prognosis.
It is well established that cytotoxicity with thiotepa, an alkylating agent similar to nitrogen mustard, correlates with the dose administered. 15 Geyer et al 16 concluded that thiotepa was inefficient in recurrent malignant pediatric tumors using the maximum conventional dose (65 mg/m 2 ). High-dose thiotepa, used as a single agent or combined with other cytotoxics and supported by hematopoietic stem cell transplantation (HSCT), has been tested in various solid pediatric tumors and the response rates were encouraging. 2, 17, 18, 19 However, no homogeneous large series has adequately evaluated the activity of thiotepa in MMT. We previously reported a phase II study of HDT in various pediatric solid tumors and some of the patients (Nos 1-7, 9) in the present study were included in that previous publication. 2 The results obtained were encouraging but the limited size of the population prohibited any firm conclusions regarding response rate. This is the first large series evaluating the anti-tumor activity of HDT in MMT. Response in 6/18 patients (33%) confirms previous data and demonstrates the efficacy of the drug used at a high dose in this type of childhood tumor. Given the small size of the population, no difference in response rate could be demonstrated in terms of histologic types. All children who achieved a significant response had metastatic disease at the time of HDT and half of the responding patients were experiencing a second or further relapse when they received HDT. The responses observed are noteworthy since these patients had particularly poor prognosis disease.
HDT has most often been included in multi-agent highdose chemotherapy regimens. [20] [21] [22] The main drawback of such a combination is that drug doses have to be attenuated to avoid cumulative toxicity. 23 Furthermore, these combinations were designed empirically and it has not been possible to analyse the efficacy of each single agent.
A few other phase II studies using high-dose single agents in MMT have been reported. Pinkerton et al 24 used HD melphalan and achieved a response rate of 44% in MMT. Hartmann et al 25 also reported a response rate of 44% for RMS with HD melphalan in a phase II study of pediatric solid tumors. Nevertheless, HD melphalan failed to have an impact on survival in MMT 4-91 study. 13 A phase II study of high-dose methotrexate was conducted in high-risk unresectable or metastatic rhabdomyosarcoma (RMS) and a response rate of 33% (4/12) was obtained. This study, 26 however, investigated 'up-front window therapy' and included only previously untreated chil-dren whose tumors should have been more sensitive to chemotherapy.
In the present study, thiotepa was used at 900 mg/m 2 . This is the maximum tolerated dose, 15 but there are no data available indicating whether a lower dose would yield the same anti-tumor efficacy or not.
Extra-hematological toxicity of HDT was essentially severe mucositis, that was never life-threatening, but necessitated frequent use of opiates to relieve severe pain. This side-effect has been well described and is known to be dose-dependent and to become problematic as soon as the 900 mg/m 2 dose is used. 15 Despite severe mucositis, no cases of severe gastrointestinal hemorrhage occurred in this series.
Conversely, cutaneous toxicity was less frequent than expected. Saarinen et al 19 reported the occurrence of erythroderma in practically every patient at a dose of 1125 mg/m 2 .
In conclusion, the present series indicates that thiotepa is an active agent in pediatric malignant mesenchymal tumors when used at a high dose. Although this HD schedule was not life-threatening, toxicity remained severe and necessitated intensive care monitoring and adapted supportive care.
HDT could be used in combination with other agents demonstrated to be efficient as single agents in phase II studies. Consolidation therapy of CR patients could therefore be investigated prospectively using combined highdose chemotherapy in patients with particularly poor prognosis stage IV MMT, namely, subjects older than 10 years at diagnosis and/or with bone or bone marrow metastases. 27 
